Related Experiment Video
Updated: May 1, 2026

Surgical Treatment of an Endolymphatic Sac Tumor
Published on: May 26, 2023
[Hurler syndrome: early diagnosis and treatment]
S Leroux1, J-B Muller1, E Boutaric1
1Service de néonatologie, hôpital Mère-Enfant, CHU de Nantes, , 38, boulevard Jean-Monnet, 44000 Nantes, France.
Insights
Hurler syndrome (MPS I) is a rare genetic disorder. Early diagnosis and treatment with enzyme replacement and stem cell therapy can stabilize symptoms and preserve cognitive development in infants.
Area of Science:
- Genetics and rare diseases
- Lysosomal storage disorders
- Pediatric medicine
Background:
- Hurler syndrome (Mucopolysaccharidosis type I) is a severe lysosomal storage disease caused by alpha-L-iduronidase deficiency.
- Glycosaminoglycan accumulation leads to progressive multi-organ dysfunction.
- MPS I incidence is approximately 1-2 per 100,000 live births.
Observation:
- A 3-week-old infant presented with feeding difficulties, coarse facial features, hypotonia, and airway obstruction.
- Clinical signs and biochemical tests confirmed MPS I, including elevated urinary GAGs and absent alpha-L-iduronidase activity.
- Genetic analysis revealed homozygosity for the p.W402X mutation in the IDUA gene.
Findings:
- The infant experienced progressive symptoms including skeletal deformities, glaucoma, and dilated cardiomyopathy.
- Enzyme replacement therapy (ERT) with laronidase at 5 months stabilized cardiac function and reduced organomegaly.
- Hematopoietic stem cell transplantation (HSCT) at 11 months preserved cognitive development.
Implications:
- This case highlights the critical role of early diagnosis in managing Hurler syndrome.
- Combined ERT and HSCT can effectively manage severe MPS I manifestations.
- Timely intervention is key to preventing irreversible organ damage and preserving neurodevelopment.
Abstract:
Hurler syndrome, the most severe form of mucopolysaccharidosis type I (MPS I), is a rare lysosomal storage disease. The overall incidence of MPS I is 0.99-1.99/100,000 live births. Accumulation of glycosaminoglycans causes the progressive dysfunction of multiple organs. We report the case of a 3-week-old newborn who was hospitalized in the Neonatal Intensive Care Unit for feeding problems. Coarse facial features and gingival hypertrophy, associated with axial hypotonia, upper airway obstruction, and moderate hepatomegaly, led to the early diagnosis of MPS I at 3 weeks of age and was confirmed by an abnormally elevated amount of dermatan and heparan sulphate in the urine and complete deficiency of alpha-L-iduronidase lysosomal enzyme activity. The child was homozygous for the p.W402X mutation, located on chromosome 4p16.3 of the alpha-L-iduronidase (IDUA) gene. The clinical condition gradually deteriorated until the age of 4 months, with thoracic and lumbar dysostoses, glaucoma, cerebral ventricular dilatation and cervical spinal stenosis, dilated cardiomyopathy, and umbilical hernia. Early diagnosis allowed enzyme replacement therapy (iaronidase, Aldurazyme(®), Genzyme) started at the age of 5 months, which provided stabilization of the heart disease, significant regression of rhinologic symptoms, and regression of hepatomegaly. Cord blood hematopoietic stem cell transplantation was performed at 11 months of age, allowing optimal preservation of cognitive development.
More Related Videos
Related Concept Videos
Huntington Disease l: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Nephrotic Syndrome II : Assessment and Medical Management
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Lysosomal Hydrolases
Rheumatic Heart Disease III: Medical Management

